Clinical Trial

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 19, 2023 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-11-13; most recent amendment 2023-10-17.
Status change: Not Yet Recruiting → Recruiting 2023-09-14
Trial Details
NCT Number NCT05624099
Lead Sponsor Fujian Cancer Hospital
Conditions Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms
Enrollment 75 participants
Start Date 2023-08-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-10-19